No information is available on the clinical use of dacomitinib during breastfeeding. Because dacomitinib is 98% bound to plasma proteins, the amount in milk is likely to be low. However, because of its potential toxicity in the breastfed infant and its half-life of 70 hours, the manufacturer recommends that breastfeeding be discontinued during dacomitinib therapy and for at least 17 days after the last dose.
关于达可替尼在母乳喂养期间的临床应用尚无可用信息。由于达可替尼与血浆蛋白的结合率为98%，其在乳汁中的含量可能较低。然而，鉴于其对母乳喂养婴儿的潜在毒性以及70小时的半衰期，制造商建议在达可替尼治疗期间及最后一剂后至少17天内停止母乳喂养。
